ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,685.88
-0.20%
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs Yen
159.8535
0.10%
Brent Oil
84.615
0.51%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Soleno Therapeutics Inc (SLNO)

  7. Soleno Therapeutics Inc (SLNO) ニュース

SLNO

Soleno Therapeutics (SLNO)

Soleno Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SLNO
日付受信時刻ニュースソース見出しコード企業名
2024/06/2506 : 18GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
2024/06/1109 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/06/1109 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/06/1109 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/06/0705 : 29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
2024/06/0421 : 00GlobeNewswire Inc.Soleno Therapeutics Set to Join Russell 3000® IndexNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/2305 : 05GlobeNewswire Inc.Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024NASDAQ:SLNOSoleno Therapeutics Inc
2024/05/2221 : 00GlobeNewswire Inc.Soleno Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/1521 : 00GlobeNewswire Inc.Soleno Therapeutics Stands with the Prader-Willi Syndrome CommunityNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/1005 : 31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLNOSoleno Therapeutics Inc
2024/05/1005 : 05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/0806 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/0705 : 58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLNOSoleno Therapeutics Inc
2024/05/0311 : 32GlobeNewswire Inc.Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
2024/05/0305 : 01GlobeNewswire Inc.Soleno Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
2024/04/3021 : 00GlobeNewswire Inc.Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeNASDAQ:SLNOSoleno Therapeutics Inc
2024/04/2921 : 00GlobeNewswire Inc.Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)NASDAQ:SLNOSoleno Therapeutics Inc
2024/04/2005 : 05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
2024/03/0906 : 05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
2024/03/0720 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
2024/03/0706 : 05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
2024/02/2222 : 00GlobeNewswire Inc.Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:SLNOSoleno Therapeutics Inc
2024/02/0106 : 19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/3106 : 57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/3007 : 47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/3007 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/3007 : 42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/3006 : 05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
2024/01/2422 : 00GlobeNewswire Inc.Soleno Therapeutics Strengthens Leadership Team with Key AppointmentsNASDAQ:SLNOSoleno Therapeutics Inc
2024/01/1806 : 06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNOSoleno Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SLNO

最近閲覧した銘柄

CCOM
US30
US 30
USI
USTECH100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
JPM
JP Morgan Chase
FX
USDEUR
US Dollar vs Euro
COIN
ETHUSD
Ethereum
AMEX
SPY
SPDR S&P 500
FX
USDJPY
US Dollar vs Yen
NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
NYSE
NKE
Nike
AMEX
XLV
Health Care Select Sector
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有